301367SZSE

Special Report on the Company's 2025 Securities and Derivatives Investment

BMC Medical Co., Ltd.·April 22, 2026·3 pages

✨ AI Summary

This report details the company's 2025 foreign exchange hedging activities, approved by the board and shareholders. The purpose is to mitigate exchange rate risks on overseas income. The approved limit is USD 250 million, with actual utilization at USD 121 million. The board confirmed compliance with regulations and no harm to shareholder interests.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Special Report on the Company's 2025 Securities and Derivatives Investment

In accordance with the "Shenzhen Stock Exchange Listed Companies Self-Regulatory Management Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other relevant regulations, the Board of Directors of Beijing Remeet Medical Technology Co., Ltd. (hereinafter referred to as the "Company") has reviewed the Company and its subsidiaries' investment in securities and derivatives for 2025. The relevant situation is hereby reported as follows:

I. Review and Approval of Securities and Derivatives Investment

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.